Rigaku Raman Upgrades Handheld Analyzer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Rigaku Raman Upgrades Handheld Analyzer


Rigaku Raman Technologies announced an updated version of the FirstGuard handheld Raman analyzer at Pittcon 2013. The analyzer operates at 1064 nm wavelength, enabling it to identify a broader range of raw materials and provide very rapid validation in comparison to 785 nm wavelength excitation products. Features include an integrated bar code reader enabling for GMP Raw Material Identification applications, user account management, upgraded data reporting and archiving, and improved data and operator security to support integration into FDA regulated manufacturing environments, the company reports. The analyzer is equipped with an integrated vial holder and hot swappable lithium ion battery, and is configured with secure software for 21 CRF part 11 compliance.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
9%
Protecting the supply chain
39%
Expedited reviews of drug submissions
9%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here